ArticleTransplant infectious disease : an official journal of the Transplantation Society
Comparative 3-Year Allograft Outcomes for Recipients of Kidneys From SARS-CoV-2 NAT-Positive Donors.
Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData demonstrates safety and short-term success of kidney transplantation (KT) from SARS-CoV-2 NAT-positive organ donors (NAT+) compared to NAT-negative donors. However, detailed reports of longer-term graft outcomes are limited and lack granular data on donor SARS-CoV-2 infection severity.
methodsWe retrospectively reviewed records from 220 recipients of KT (KTRs) at our institution from February 1, 2021, to January 31, 2022. We compared 1- and 3-year allograft-specific outcomes for KTRs from NAT+ (N = 59), CoV-COD (COVID as cause of death) (N = 56), and NAT-neg (N = 105) donors. We reviewed and compared pathology findings for allograft biopsies for all groups up to 1 year. We examined the association of eGFR at 3 years with CoV-donor status using multivariable linear regression.
resultsAt 1 year, there was no difference in rejection or kidney pathologies by CoV-donor status. At 3 years, there was no difference in patient death or graft loss by group. For subjects without graft loss, eGFR at 3 years for NAT+, CoV-COD, and NAT-neg donors was 54.8 (21.8), 45.6(17.9), and 48.4 (23.3) mL/min/m
conclusionsWe found no significant difference in pathological findings or 3-year allograft outcomes following KT from NAT-negative, NAT+, or CoV-COD donors. Despite modestly reduced eGFR for COV-COD on unadjusted analysis, kidneys from donors with a spectrum of COVID severities did not experience significantly poorer allograft outcomes over 3 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.